GTO ID | GTC2857 |
Trial ID | NCT05140187 |
Disease | CMV Infection |
Altered gene | CMV |
Therapeutic/Target gene | Target gene |
Therapy | TCR-T cell |
Treatment | CMV TCR-T cells |
HLA | HLA-A*02:01|HLA-A*24:02|HLA-A*11:01 |
Phase | Phase1 |
Recruitment status | Recruiting |
Title | Adoptive Immunotherapy With Donor-derived CMV-TCR-T Cells for Patients With CMV Infection After Allogenic HSCT |
Year | 2021 |
Country | China |
Company sponsor | Chinese PLA General Hospital |
Other ID(s) | S2021-344-01 |
Vector information | |||
|
Cohort1: dose level 1 | |||||||||||
|
|||||||||||
Cohort2: dose level 2 | |||||||||||
|
|||||||||||
Cohort3: dose level 3 | |||||||||||
|